Conjugate chemistry and cellular processing of EGF-dextran.
Conjugates with specific binding to the epidermal growth factor receptor, EGFR, of interest for radionuclide based imaging and therapy were prepared using mouse epidermal growth factor, mEGF, and dextran. In one type of conjugate, mEGF was coupled to dextran by reductive amination in which the free amino group on the mEGF N-terminal reacted with the aldehyde group on the reductive end of dextran. The end-end coupled conjugate could be further activated by the cyanopyridinium agent CDAP, thereby introducing tyrosines to the dextran part. In the other type of conjugate, the cyanylating procedure using CDAP was applied, first to activate dextran and then allowing for the amino terminus of mEGF to randomly attach to the dextran. In the latter case, radionuclide-labelled tyrosines or glycines could be added in the same conjugation step. All types of mEGF-dextran conjugates had EGFR-specific binding since the binding could be displaced by an excess of non-radioactive mEGF. The conjugates were to a large extent internalized in the test cells and the associated radioactivity was retained intracellularly for different times depending on both the type of cells and conjugate applied. Different intracellular 'traffic routes' for the radionuclides are discussed as well as applications for both imaging and therapy.
Carlsson
J
J
Unit of Biomedical Radiation Sciences, Uppsala University, Sweden. Jorgen.Carlsson@bms.uu.se
Blomquist
E
E
Gedda
L
L
Liljegren
A
A
Malmström
P U
PU
Sjöström
A
A
Sundin
A
A
Westlin
J E
JE
Zhao
Q
Q
Tolmachev
V
V
Lundqvist
H
H
D001246:Astatine / Q000627:therapeutic use; D003911:Dextrans / Q000378:metabolism*; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D003911:Dextrans; D007457:Iodine Radioisotopes; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D001246:Astatine